Alzamend Neuro Inc Ordinary Shares ALZN
About Quantitative Ratings
Morningstar Quantitative Ratings for Stocks are generated using an algorithm that compares companies that are not under analyst coverage to peer companies that do receive analyst-driven ratings. Companies with quantitative ratings are not formally covered by a Morningstar analyst, but are statistically matched to analyst-rated companies, allowing our models to calculate a quantitative moat, fair value, and uncertainty rating.
Is it the right time to buy, sell, or hold?
Start a free trial of Morningstar Investor to unlock exclusive ratings and continuous analyst coverage to help you decide if ALZN is a good fit for your portfolio.
News
Trading Information
- Previous Close Price
- $0.71
- Day Range
- $0.70–0.73
- 52-Week Range
- $0.65–11.91
- Bid/Ask
- $0.70 / $0.73
- Market Cap
- $4.81 Mil
- Volume/Avg
- 22,924 / 59,339
Key Statistics
- Price/Earnings (Normalized)
- —
- Price/Sales
- —
- Dividend Yield (Trailing)
- —
- Dividend Yield (Forward)
- —
- Total Yield
- —
Company Profile
Alzamend Neuro Inc is an early clinical-stage biopharmaceutical company. It is focused on developing novel products for the treatment of neurodegenerative diseases and psychiatric disorders, including Alzheimer's. Its mission is to develop and market safe and effective treatments. The company's pipeline consists of two novel therapeutic drug candidates, AL001 - a patented ionic cocrystal technology delivering lithium via a therapeutic combination of lithium, proline and salicylate, and AL002 - a patented method using a mutant-peptide sensitized cell as a cell-based therapeutic vaccine that seeks to restore the ability of a patient's immunological system to combat Alzheimer's.
- Sector
- Healthcare
- Industry
- Biotechnology
- Stock Style Box
- —
- Total Number of Employees
- 7
- Website
- https://www.alzamend.com
Valuation
|
Metric
|
ALZN
|
|---|---|
Price/Earnings (Normalized) | — |
Price/Book Value | — |
Price/Sales | — |
Price/Cash Flow | — |
Price/Earnings
No chart available
Financial Strength
|
Metric
|
ALZN
|
|---|---|
Quick Ratio | 0.07 |
Current Ratio | 0.16 |
Interest Coverage | −1,353.64 |
Quick Ratio
ALZN
Profitability
|
Metric
|
ALZN
|
|---|---|
Return on Assets (Normalized) | −293.33% |
Return on Equity (Normalized) | −2,989.49% |
Return on Invested Capital (Normalized) | −2,130.33% |
Return on Assets
ALZN
Biotechnology Industry Comparables
|
Ticker
|
Name
|
Morningstar Rating for Stocks
|
Capital Allocation
|
Economic Moat
|
Market Cap
|
|---|---|---|---|---|---|
NVO
| Novo Nordisk A/S ADR | Nbkztdvc | Fksk | $562.4 Bil | |
VRTX
| Vertex Pharmaceuticals Inc | Pdsxjyrj | Mrhcwh | $103.6 Bil | |
REGN
| Regeneron Pharmaceuticals Inc | Nzwkfpkcr | Bbnhfz | $99.5 Bil | |
MRNA
| Moderna Inc | Ktydmpjv | Sfsb | $38.8 Bil | |
ARGX
| argenx SE ADR | Wlfbqxhx | Kxgb | $22.3 Bil | |
BNTX
| BioNTech SE ADR | Ckxhtyxqv | Gxsn | $21.2 Bil | |
ALNY
| Alnylam Pharmaceuticals Inc | Fyngzwf | Bzlzf | $18.2 Bil | |
BMRN
| Biomarin Pharmaceutical Inc | Bpkspfbb | Dhywjd | $17.3 Bil | |
RPRX
| Royalty Pharma PLC Class A | Ctfhxwknm | Fbhzw | $12.5 Bil | |
INCY
| Incyte Corp | Tzdlytgpt | Dlvvxl | $11.6 Bil |